European journal of clinical investigation
-
Eur. J. Clin. Invest. · Jan 2023
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma.
To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. ⋯ Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.
-
Eur. J. Clin. Invest. · Jan 2023
Comparison of pan-immune-inflammation with other inflammation markers of long-term survival after ST-segment elevation myocardial infarction.
Atherosclerosis is a process that causes coronary artery disease and is associated with the inflammatory response. In this study, we aimed to evaluate the association of Pan-Immune-Inflammation Value (PIV) with in-hospital and long-term mortality in STEMI patients. ⋯ Our study reveals that PIV is a better predictor of mortality in STEMI patients. Prospective studies are needed to validate this biomarker.
-
Eur. J. Clin. Invest. · Jan 2023
Early pregnancy triglycerides and not fructosamine are associated with birth weight (with foetal sexual dimorphism).
We evaluated whether maternal triglycerides (TGs) or fructosamine (measured in early pregnancy) predominantly contribute to birth weight (BW), in a foetal sexual dimorphism. ⋯ Maternal TGs were more dominant (compared to fructosamine) in its association with BW (measured in early physiological pregnancy) and more prominently present when carrying a male foetus. These remarkable observations warrant more future research, especially in obese patients at risk for gestational diabetes.
-
Eur. J. Clin. Invest. · Jan 2023
A comprehensive and longitudinal cardiac magnetic resonance imaging study of the impact of coronary ischemia duration on myocardial damage in a highly translatable animal model.
We performed a comprehensive assessment of the effect of myocardial ischemia duration on cardiac structural and functional parameters by serial cardiac magnetic resonance (CMR) and characterized the evolving scar. ⋯ Sixty-minute LAD coronary occlusion already induces cardiac structural and functional alterations with longer ischemic time (120 min) causing adverse LV remodelling.